Form 4: Blend Labs Officer Sells Shares Under 10b5-1 Plan

Blend Labs' Principal Accounting Officer, Oxana Tkach, sold 2,500 shares of Class A Common Stock for $3.09 per share under a pre-arranged trading plan.

Summary

• Oxana Tkach, the Principal Accounting Officer of Blend Labs, Inc. (BLND), reported a sale of company stock.
• The transaction involved the disposition of 2,500 shares of Class A Common Stock.
• The shares were sold at a price of $3.09 per share.
• Following this transaction, Oxana Tkach beneficially owns 77,017 shares of Class A Common Stock.
• The sale was executed on January 7, 2026.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Tkach on September 9, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. A Form 4 reporting a sale under a pre-arranged 10b5-1 plan is generally considered a routine event for personal financial management and does not typically indicate a change in management's outlook on the company's prospects, especially for a relatively small number of shares.

Industry Context

This filing reports a routine insider transaction by a corporate officer, which is a common occurrence in publicly traded companies. The use of a Rule 10b5-1 trading plan indicates a pre-scheduled sale, often for personal financial planning, rather than a reaction to immediate company performance or market conditions.

Stakeholder Impact

• Shareholders: The sale of 2,500 shares by a Principal Accounting Officer under a 10b5-1 plan is a minor transaction and is unlikely to have a significant impact on the company's stock price or investor sentiment.

Key Dates

Recommendation

The filing is a routine Form 4 reporting an insider stock sale under a Rule 10b5-1 trading plan. This type of transaction is typically pre-scheduled for personal financial planning and does not usually reflect a change in the insider's view of the company's future performance. Given the small number of shares sold relative to the company's total outstanding shares and the pre-planned nature, this event alone does not provide a strong signal for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Blend Labs, Inc.'s financial performance and strategic outlook.

Keywords

Blend Labs, BLND, Form 4, Insider Trading, Stock Sale, Oxana Tkach, 10b5-1 Plan, Principal Accounting Officer